Drugs / Mitoxantrone Hydrochloride Liposome Injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04668690 | Apr 2021 → Dec 2027 expected | peripheral T-cell lymphoma, not otherwise specified | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitoxantrone Hydrochloride Liposome Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04668690 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT04668690 ↗ |